THERMO FISHER SCIENTIFIC INC.
No SEC Form 4 filings for $TMO in the last 30 days.
See all $TMO insider activity →ClearBridge Investments' Q3 2026 commentary noted Thermo Fisher Scientific (TMO) as a strong performer, benefiting from Q2 earnings beat and Q3 guidance. TMO closed at $676.76, up 10.48% monthly and 23.56% yearly, with a $250.23B market cap. The company's biopharma and pharmaceutical segments showed resilience. TMO is held by 118 hedge funds, ranking 34th in popularity.
Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.
Thermo Fisher Scientific (TMO) shares rose 1.1% to $662.27 after JPMorgan added it to its October growth selections. Q2 revenue grew 10% to $11.99B, with operating income up 14% to $2.09B. The company introduced AI-driven Orbitrap platforms, aiming for sustained growth and margin gains.
Over the past 7 days, AlphAI's AI scored 12 news stories mentioning TMO (THERMO FISHER SCIENTIFIC INC.). Coverage has skewed bullish: 6 bullish, 6 neutral, and 0 bearish.
Recent TMO coverage spans technology, financial news and earnings.
No new material information; reiterates existing guidance.
Neutral to modestly positive as the deal adds revenue but is a small portion of overall CRO business.
Modest upside as analyst endorsement reinforces recent earnings momentum.
Growth rating driven by strong guidance and a joint‑venture with Mayo Clinic.
The launch may boost demand for Thermo Fisher's cell culture products and support revenue growth in its biotech supplies segment.
AlphAI scores every news story that mentions TMO with an AI model for sentiment and relevance, and aggregates insider trades from THERMO FISHER SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ClearBridge Investments' Q3 2026 commentary noted Thermo Fisher Scientific (TMO) as a strong performer, benefiting from Q2 earnings beat and Q3 guidance. TMO closed at $676.76, up 10.48% monthly and 23.56% yearly, with a $250.23B market cap. The company's biopharma and pharmaceutical segments showed resilience. TMO is held by 118 hedge funds, ranking 34th in popularity.
1 min readQuantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.
2 min readThermo Fisher Scientific (TMO) shares rose 1.1% to $662.27 after JPMorgan added it to its October growth selections. Q2 revenue grew 10% to $11.99B, with operating income up 14% to $2.09B. The company introduced AI-driven Orbitrap platforms, aiming for sustained growth and margin gains.
1 min readJPMorgan released its October stock picks, adding American Express (AXP), Thermo Fisher Scientific (TMO), and Liberty Energy (LBRT) to its 'overweight' list. AXP is seen as a value play despite a 18% YTD decline, while TMO and LBRT are growth picks due to strong sector trends. The bank advises diversification across sectors for Q4.
2 min readThermo Fisher Scientific launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media for CHO-K1 cell lines. The panel, available in liquid and dry powder formats, supports cell growth and protein production, with combinations showing up to 73% higher titer and 202% higher cell density in tests. The company aims to provide flexible, scalable solutions for biologics developers.
1 min readMayo Clinic and Thermo Fisher Scientific launched Precure LLC to collect and analyze multi-omics data from one million biospecimens, aiming to identify early disease signals. Mayo Clinic will own a majority stake, while Thermo Fisher will provide proteomics expertise. The partnership seeks to accelerate drug development and improve early diagnosis.
2 min readThermo Fisher Scientific (TMO) launched the Gibco CHO-K1 Catalog Panel, a product designed to enhance cell growth and protein production. The company reported Q2 2026 revenue of $11.99 billion, up 10% YoY, with adjusted EPS at $6.03. The new product aligns with TMO's strategy of high-margin consumables, though bears cite profitability pressures and macroeconomic uncertainties.
3 min readTime Out Group's (TMO) Media arm returned to adjusted EBITDA profit with a 17% revenue increase to £21m. Group revenue was £72m, flat year-over-year. The company expanded its global audience by 31% to 280 million and opened new locations. CEO Chris Ohlund attributed the turnaround to strategic progress and operational improvements.
2 min readThermo Fisher Scientific opened a $130M vaccine manufacturing facility in Singapore, enhancing regional vaccine production. The plant complements investments by Sanofi and BioNTech, boosting Singapore's biotech hub status. Deputy PM Heng Swee Keat highlighted the facility's role in supply chain resilience and future health crisis preparedness.
2 min readPfizer (PFE) and Thermo Fisher (TMO) are recovering post-pandemic. TMO's Q2 revenue rose 10% to $11.99B, EPS up 13% to $6.03. PFE's Q2 revenue up 3% to $15.03B, non-COVID revenue up 5%. Both raised outlooks. TMO shows clearer momentum; PFE's turnaround depends on newer products and cost cuts.
3 min read
